放射性ADME证明了ARV-110的高耐药性,尽管口服生物可用性低
Yifei He1,2, Yuandong Zheng1, Chenggu Zhu3
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Journal of medicinal chemistry
|July 29, 2024
概括
针对蛋白质溶解的嵌合体 (PROTACs) 显示出有前途的治疗方法. 尽管口服吸收较差,但PROTACs (如巴夫德胺) 显示出更高的疗效,优先考虑目标特异性而不是生物可用性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 药物开发 药物开发
背景情况:
- 化向化体 (PROTACs) 是一种新兴的疗法,具有潜在的临床应用.
- 高分子量和低溶解度限制了PROTACs的口服生物可用性.
- 了解吸收,分布,新陈代谢和分泌 (ADME) 特性对于 PROTAC 开发至关重要.
研究的目的:
- 为了合成和评估C标记巴甲胺 (ARV-110) 的ADME特征,一个模型 PROTAC.
- 评估食物对ARV-110口服生物可用性的影响.
- 为了比较ARV-110与恩扎胺的治疗疗效和药物动力学概况.
主要方法:
- 合成C标记的甲胺 (ARV-110).
- 在老鼠中进行口服管理研究,以确定口服生物可用性,与食物一起和没有食物.
- 定量全身无线图 (QWBA) 用于评估瘤中的药物分布.
- 与恩扎胺的药理动力学和药理动力学比较.
主要成果:
- 食物摄入使大鼠的ARV-110口服生物可用性从10.75%增加到20.97%,这仍然不足于最佳水平.
- 与恩扎胺相比,ARV-110在较低剂量下显示出明显更好的治疗效果.
- QWBA证实了ARV-110在皮下前列腺瘤中的特定分布.
- 发现PROTAC的特异性和活性对于治疗成功比高口服吸收更为关键.
结论:
- 即使口服生物可用性有限,PROTACs也可以达到强大的治疗效果.
- 使用放射性标记化合物的药物代谢和药理动力学 (DMPK) 研究对于PROTAC药物开发至关重要.
- 具体性和目标参与是PROTAC疗效的关键驱动因素,这表明了口服药物开发的新范式.
相关概念视频
Bioavailability: Overview
2.7K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.7K
Factors Influencing Drug Absorption: Presystemic Elimination
201
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
201
Non-Oral Extravascular Drug Absorption Routes
207
Non-oral extravascular routes, which encompass sublingual, buccal, topical, intramuscular, and inhalation methods, primarily utilize passive diffusion to transport drugs into the systemic circulation. The absorption rates and effectiveness of these routes depend on the drug's physicochemical properties, as well as the patient's anatomical and pathophysiological state.
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
207
Drug Absorption: Overview
554
The process of drug absorption signifies the transition of a drug from its site of administration into the plasma. This process is influenced by various factors, including the route of administration, the anatomy of the absorption site, the mechanism of absorption, gut motility, and the drug's physicochemical properties.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
554
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
191
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
191
Factors Influencing Drug Absorption: Drug Dissolution
454
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
454

![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)
